Scientific reports · 2026
Propolis nanoemulsion and mesenchymal stem cell conditioned medium promote osteoblastogenesis against lipopolysaccharide-induced osteolysis in hyperglycemic rats.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alhasyimi Ananto Ali, Nugraha Alexander Patera, Farmasyanti Cendrawasih Andusyana, Rosyida Niswati Fathmah, Susanto Hendri, Artasasta Muh Ade, Situmorang Putri Cahaya, Shariff Khairul Anuar
Аннотация
Hyperglycemia is known to worsen lipopolysaccharide (LPS)-induced inflammatory osteolysis. However, regenerative therapy with human umbilical cord mesenchymal stem cells conditioned medium (HUCMSCs-CM) and Tetragonula biroi propolis nanoemulsion (PNE) may suppress inflammatory osteolysis with hyperglycemia. This study investigated how HUCMSCs-CM and PNE affected the osteoblastogenesis markers in rats with hyperglycemia and inflammatory osteolysis. Twenty-eight healthy male rats (1–2 months old) were divided into seven groups: NC (negative control), LP (100 µL LPS), HG (> 230 mg/dL), LH (100 µL LPS with hyperglycemia), LHH (LPS, hyperglycemia, and 100 µL HUCMSCs-CM), LHN (LPS, hyperglycemia, and 100 µL PNE), and LHHN (LPS, hyperglycemia), and 100 µL LPS from Escherichia coli was used to induce calvarial osteolysis. PNE and HUCMSCs-CM were prepared and administered subcutaneously into the calvaria. Thereafter, hyperglycemia was induced via intraperitoneal administration of 30 mg/kg of streptozotocin for 1 week. The rats were sacrificed on day 8, and ELISA was used to measure Coll1a1, ALP, and osteopontin in the blood samples. Immunohistochemistry was employed to examine the osteoblastogenesis markers; RUNX-2, osterix, osteonectin, and osteocalcin. In the LPS-induced inflammatory osteolysis model with hyperglycemia, administration of HUCMSCs and PNE significantly increased osteoblastogenesis markers (P ≤ 0.05). The combination treatment showed the most pronounced effect, enhancing serum Coll1a1, ALP, and osteopontin levels, as well as RUNX-2, osterix, osteonectin, and osteocalcin expression. These findings indicate that HUCMSCs-CM and PNE synergistically promote osteoblastogenesis in hyperglycemia-aggravated inflammatory osteolysis and may represent a promising regenerative therapeutic strategy for inflammatory bone loss under compromised metabolic conditions.